How should drop (atonic) seizures be acutely managed and what are the first‑line maintenance treatment options?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Drop (Atonic) Seizures

For drop attacks in Lennox-Gastaut syndrome and similar epilepsies, use topiramate (6 mg/kg/day) or lamotrigine (50-400 mg/day adjusted for weight and valproate use) as first-line maintenance therapy, with valproic acid as an alternative initial option 1.

Acute Management

For any drop seizure evolving into status epilepticus or prolonged seizure activity:

  • Benzodiazepines are the first-line acute treatment 2, 3
    • Administer via IV, intramuscular, rectal, or intranasal routes
    • Short-acting benzodiazepines are preferred 4
    • Time-critical intervention: initiate immediately to prevent progression

If seizures persist after benzodiazepines:

  • Second-line options include phenytoin/fosphenytoin, valproate, or levetiracetam 2
  • These three agents show similar efficacy (approximately 50% seizure cessation) 2
  • For refractory cases, IV anesthetics including ketamine are necessary 2

First-Line Maintenance Treatment

Level A Evidence (Strongest Recommendations)

Topiramate and lamotrigine are the only medications with Level A evidence for drop attacks 1:

  1. Topiramate: 6 mg/kg/day

    • Demonstrated 14% reduction in drop attacks versus 5.1% increase with placebo
    • 55% of patients achieved 50% responder rate in open-label follow-up
    • 56% median reduction in drop attacks 1
  2. Lamotrigine: 50-400 mg/day (dose-adjusted for weight and valproate co-administration)

    • Effective in reducing seizures in Lennox-Gastaut syndrome
    • Critical caveat: 9% rash rate, including serious cases and Stevens-Johnson syndrome in pediatric patients 1
    • Requires slow titration, especially with valproate

Alternative First-Line Options

Valproic acid is widely used in clinical practice:

  • 77% of pediatric neurologists in Saudi Arabia use it as first-line 5
  • Broad-spectrum efficacy for generalized epilepsies
  • Important limitation: Category D teratogenicity (both animal and human evidence) 1

Levetiracetam is increasingly favored:

  • Commonly included in initial management protocols 5
  • Better safety profile than older agents
  • No Level A evidence specifically for drop attacks, but widely used based on clinical experience

Clinical Decision Algorithm

Step 1: Confirm drop attack type

  • True atonic seizures are rare; most are epileptic spasms or seizures with increased muscle tone 6
  • Video-EEG-EMG monitoring provides accurate diagnosis when feasible

Step 2: Choose initial maintenance therapy based on:

  • Lennox-Gastaut syndrome confirmed: Topiramate or lamotrigine (Level A) 1
  • Female of childbearing potential: Avoid valproate; prefer topiramate or lamotrigine
  • Concern for rash/Stevens-Johnson: Avoid lamotrigine; use topiramate or valproate
  • Rapid titration needed: Levetiracetam or valproate (lamotrigine requires slow titration)

Step 3: Add adjunctive therapy if monotherapy fails:

  • Clobazam, rufinamide commonly used 5
  • Consider ketogenic diet for refractory cases 7

Step 4: Surgical evaluation for drug-resistant cases:

  • Corpus callosotomy is effective for refractory epileptic drop attacks, especially in Lennox-Gastaut syndrome 6, 8
  • Total callosotomy shows favorable seizure cessation rates in bilateral malformations of cortical development 8

Critical Pitfalls to Avoid

  • Do not use carbamazepine: Known to cause seizure worsening in Lennox-Gastaut syndrome and generalized epilepsies 1
  • Do not delay lamotrigine titration: Rapid titration increases Stevens-Johnson syndrome risk
  • Do not assume all drop attacks are atonic: Most are epileptic spasms requiring different pathophysiologic consideration 6
  • Do not use general anesthesia for continuous partial epilepsy 9

Evidence Quality Considerations

The strongest evidence comes from the 2004 AAN/AES guidelines 1, which provide Level A recommendations based on Class I studies. While older, these remain the only Level A evidence specifically for drop attacks. The 2024 status epilepticus guidelines 9 inform acute management but don't specifically address chronic drop attack treatment. Recent observational data 5 shows real-world practice patterns but lacks the rigor of controlled trials. The paucity of recent high-quality trials for drop attacks means we must rely on this older but methodologically sound evidence 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.